Research programme: nucleotide therapeutics - enGene

Drug Profile

Research programme: nucleotide therapeutics - enGene

Alternative Names: EG 10; EG-02; EG-12; GEMS™-Insulin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator enGene
  • Developer enGene; Janssen Biotech
  • Class DNA; Nucleotides; Proteins; RNA
  • Mechanism of Action Glucagon receptor antagonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Chronic obstructive pulmonary disease; Coeliac disease; Cystitis; Diabetes mellitus; Inflammatory bowel diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in Canada (Intraduodenal, Spray)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Canada
  • 04 Nov 2017 No recent reports of development identified for research development in Cancer in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top